What class is Trelegy Ellipta?
Trelegy Ellipta is a combination inhaler used for chronic respiratory disease. It belongs to the class of inhaled maintenance therapies for COPD and asthma that combine:
- An inhaled corticosteroid (ICS)
- An inhaled long-acting muscarinic antagonist (LAMA)
- An inhaled long-acting beta-2 agonist (LABA)
In other words, Trelegy Ellipta is an ICS/LABA/LAMA “triple therapy” inhaler. [1]
What drugs make up Trelegy Ellipta’s class (ICS, LAMA, LABA)?
Trelegy Ellipta’s formulation is built from three medicine types commonly grouped under triple therapy for COPD:
- Inhaled corticosteroid (anti-inflammatory)
- Long-acting muscarinic antagonist (bronchodilator)
- Long-acting beta-2 agonist (bronchodilator)
This ICS/LAMA/LABA pairing is the reason Trelegy is categorized as a triple-therapy inhaler for maintenance treatment. [1]
Which conditions is Trelegy Ellipta used for (same class, different indications)?
Because it’s a triple-therapy inhaler (ICS/LAMA/LABA), Trelegy Ellipta is used as a long-term maintenance treatment in people who have COPD and in certain patients with asthma who need an inhaled controller regimen that includes both bronchodilators and an inhaled steroid. [1]
How does this class compare with single or dual inhalers?
Trelegy’s “triple” designation separates it from:
- Single-inhaler bronchodilators (typically just one of the long-acting pathways)
- Dual therapies (ICS/LABA or LABA/LAMA)
Trelegy combines all three categories in one device, which is why it sits in the higher-intensity maintenance inhaler category within COPD/asthma controller therapy. [1]
Where to check patents or product details for Trelegy Ellipta
If you’re researching the product’s market status or patent-related questions, DrugPatentWatch.com tracks details for many branded medicines, including Trelegy Ellipta. [2]
Sources:
[1] https://www.tevapro.com/products/trelegy-ellipta
[2] https://www.drugpatentwatch.com/